AUTHOR=Chen Ting , Chen Jie , Liu De-sheng , Shu Yan-ling , Fu Mao-yue , Gou Hai-jun , Lei Kai-jian , Jia Yu-ming 

TITLE=Successful therapy using high-dose furmonertinib for non-small cell lung cancer with leptomeningeal metastasis: a case report and literature review

JOURNAL=Frontiers in Oncology

VOLUME=Volume 13 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1233198

DOI=10.3389/fonc.2023.1233198

ISSN=2234-943X

ABSTRACT=Background: Lung cancer is the second most common malignant tumor and carries the highest mortality worldwide. Among its subtype, lung adenocarcinoma is the most prevalent. Leptomeningeal metastasis (LM) is rare and characterized by a dismal prognosis, with an overall survival typically spanning 4 to 6 weeks without treatment.However, in specific cases, survival can be extended to 4 to 6 months with appropriate therapy. The recent approval of third-generation tyrosine kinase inhibitors (TKIs), such as osimertinib, aumolertinib, and furmonertinib, has brought promising treatment options for individuals with non-small cell lung cancer (NSCLC) who develop LM after developing resistance to first-and second-generation TKIs. These third-generation TKIs exhibit enhanced ability to penetrate the blood-brain barrier (BBB), opening up new avenues for managing this challenging condition.